Skip to content

Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance

A Prospective Study of Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01687049
Enrollment
60
Registered
2012-09-18
Start date
2013-01-31
Completion date
2017-12-31
Last updated
2012-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Keywords

nonmetastatic, localized, prostate, active surveillance

Brief summary

Agents that inhibit cholesterol synthesis are being investigated in cancers dependent upon cholesterogenesis. Red yeast rice (RYR), is a reddish-purple fermented rice, containing statins which are known to inhibit cholesterol synthesis. Laboratory studies have also shown that RYR has direct effects on androgen dependent and androgen independent prostate cancer cells, inhibiting their growth. It is thought that RYR may have clinical benefit in those subjects with localized prostate cancer who have chosen to be managed by active surveillance.

Detailed description

Red yeast rice has been promoted as a safe and effective alternative to statin therapy in the treatment of hypercholesterolemia. Red yeast rice has the potential to slow prostate cancer growth by inhibiting cholesterol and androgen biosynthesis. There is a strong rationale for the use of RYR in patients being managed with active surveillance for localized, low risk, prostate cancer. To date, no human studies utilizing RYR in this setting have been reported.

Interventions

Sponsors

Dr. Laurence Klotz
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
19 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* histologically diagnosis of prostate adenocarcinoma * being monitored by active surveillance for favourable risk prostate cancer * tumour material from most recent prostate biopsy available with sample * scheduled to have an active surveillance mandated transrectal ultrasound (TRUS) guided biopsy within 6 - 12 months of Day 1 of the study

Exclusion criteria

* previous malignancy in the past 5 years * no previous or concurrent treatment for prostate cancer * inability to undergo TRUS biopsy * ECOG \> 2 * known or previous history of liver disease

Design outcomes

Primary

MeasureTime frameDescription
Expression of Ki-67 and p27 biomarkers6 monthsDetermine effect of red yeast rice therapy on expression of ki67 and p27 biomarkers in a post-treatment biopsy

Secondary

MeasureTime frameDescription
PSA kinetics6 monthsDetermine effect of red yeast rice daily therapy on PSA kinetics in men on active surveillance for localized prostate cancer
Presence of prostatic interepithelial neoplasia6 monthsTo evaluate the effect of red yeast rice daily therapy on grade and the presence of prostatic intraepithelial neoplasia (PIN) in post treatment biopsy
Expression of hs-CRP and cardiac CRP6 monthsTo assess the effect of red yeast rice therapy on the expression of high sensitivity C-reactive protein (hs-CRP) and cardiac C-reactive protein (CRP) in serum

Countries

Canada

Contacts

Primary ContactMarlene Kebabdjian, BA
marlene.kebabdjian@sunnybrook.ca416-480-6100

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026